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Ocular Toxoplasmosis: An Update 




Ocular toxoplasmosis remains to be the most common cause of infectious uveitis 
in immunocompetent individuals with highly variable prognosis. The transmission 
mode can be either congenital or acquired. A precise diagnosis of the disease is 
necessary to opt effective and rapid treatment. While ocular toxoplasmosis usually 
presents in the classic form, it may as well present in variable clinical spectrum. The 
diagnosis can be suspected by the ocular inflammatory clinical presentation as well 
as multimodal imaging. However, serologic tests including intraocular fluid testing 
may be needed. Treatment includes combination of systemic antiparasitic and anti-
inflammatory drugs with variable effectivity. More recently, intravitreally antimi-
crobials may be used. The chapter aims to layout the different clinical presentations 
and complications of ocular toxoplasmosis. Diagnostic techniques and different 
antimicrobial combinations for treatment will also be discussed.
Keywords: ocular toxoplasmosis, clinical presentation, diagnosis, treatment
1. Introduction
Approximately 25 to 30% of the world’s human population is infected by 
toxoplasma [1]. Ocular toxoplasmosis is one of the most common cause of posterior 
uveitis caused by an intracellular parasite, toxoplasma gondii [2, 3].
1952, Helenor Campbell Wilder (later Helenor Campbell Wilder Foerster) 
confirmed the growing suspicion that toxoplasma gondii was a cause of uveitis 
in otherwise healthy adults by identifying the presence of both trophozoites and 
brachyzoites in enucleated eyes, that suffered severe intraocular inflammation [4].
Retinitis is the most common manifestation of ocular toxoplasmosis with vitritis. 
Factors that may influence visual prognosis include severity of the inflammation, 
size of the lesion and site of the inflammation. Also, progression to complications 
such as a neovascularization, vitreomacular traction, retinal detachment, glaucoma 
and cataract renders worse visual prognosis. Multimodal imaging can assist in 
meticulously evaluating and studying the extent of intraocular damage imposed by 
toxoplasma inflammation. Laboratory testing of intraocular fluid has been widely 
studied and employed, including PCR testing and detection of intraocular antibod-
ies using Goldmann-Witmer coefficient (GWC), to enable more precise diagnosis 
Ocular toxoplasmosis has a self-limiting nature, treatment can help rapid control 
of inflammation specially if the retinitis involves the posterior pole. Treatment 
includes different combinations of antimicrobials; none have can prevent 
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recurrences, but some combinations have shown more effective reduction in the 
size of the retinal lesion in comparison to other combinations or no treatment [5].
2. Life cycle and mode of transmission
Toxoplasma exists in 3 infectious forms including sporozoites, which are con-
tained within oocysts, tachyzoites and bradyzoites, which reside in tissue cysts. 
Oocysts are produced only in cat intestines and become infectious when defecated 
by cats. Tachyzoites are the fastest replicating form and responsible for systemic 
dissemination and active tissue infection in intermediate hosts. Tachyzoites can 
enter almost any type of host cell and multiply until the host cell is filled with para-
sites. Lysis of the host cell results in tachyzoite release followed by reentry into a 
new host cell. As a result of this cycle, multifocal tissue necrosis may occur. The host 
usually limits this phase of infection, then the parasite enters the dormant form, 
named bradyzoites, and gets isolated in tissue cysts. Cysts may contain hundreds 
of bradyzoites. These cysts usually cause no host reaction and may remain dormant 
throughout the life of the host [6].
The infection may be acquired or congenital by vertical transmission to the 
fetus. However, reports have supported the view that acquired infections might be a 
more important cause of ocular diseases than congenital [7–9].
Acquired infection occurs by consumption of raw meat containing cysts or 
ingestion of water or food contaminated by oocytes [9, 10]. Once the active parasite 
has invaded the body, it will spread via the blood stream, and due to a high affinity 
for cerebro- and retinovascular endothelial cells, can become established within the 
retina [10]. Following invasion of the parasite into the eye, the tachyzoite remains 
latent in the cyst under the control of the immune response of host [11–13]. In event 
of trigger of cyst rupture, the tachyzoite is converted to bradyzoite, and the inflam-
matory response is activated [5, 14].
3. Clinical presentation and phenotypes
Congenital- transplacental transmission occurs in 40–70%, while acquired 
ocular involvement was reported in 1–21% [15]. However, each entity has signifi-
cantly different clinical manifestation. A study conduct in southern Brazil reported 
lower prevalence of ocular toxoplasmosis in children been 5.1% below the age of 13 
and 21.3% above the age of 13, concluding that ocular toxoplasmosis is a sequela of 
postnatal rather than congenital infection [7].
3.1 Congenital ocular toxoplasmosis
Ocular lesions are the most frequent manifestations of congenital toxoplasmosis 
[16, 17]. Vertical transmission of toxoplasmosis occurs during primary infection 
in pregnant women, and generally the maternal disease goes unnoticed. When 
pregnant women become infected in the first trimester, the frequency of fetal infec-
tion goes up to 15–20%, in the second up to 25%, and in the third up to 65–70%. The 
most compromised fetuses are those who are infected earlier [1, 18, 19].
Besides retinochoroiditis, other ocular manifestations of congenital toxoplasmo-
sis are described, such as microphthalmia, optic nerve atrophy, and abnormalities 
of the iris, cataract, and strabismus [17, 20–24].
However, typical presentation in the retina is an atrophic hyperpigmented 
scarred macular lesion that is described as ‘wagon-wheel’ lesion caused by 
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congenital toxoplasmosis. It shows a central area composed of glial and pigmented 
material connected by pigmented strands to a peripheral ring of pigment at the 
edge of the lesion. Figure 1. A study designed to detect ocular involvement in 
infants with congenital toxoplasma reported that ocular involvement occurred in 
70.4% of the cases, with mean age of active lesion at 1.4 months. Bilateral involve-
ment occurred in 15.7% of the patients, mainly involving the papillomacular bundle 
in 76.3%. The retinochoroiditis lesions were active in 15.7% of the eyes and had 
healed in 84.3% [25].
It is worth mentioning that new lesions continue to appear well after the age of 
5 years, likely with severe visual impairments. Therefore, screening of women for 
toxoplasmosis before pregnancy is advisable [26].
A significant reduction in prevalence and severity of the disease has been 
attributed to prenatal and neonatal treatment maintained throughout the first year 
of life [27–29].
3.2 Acquired toxoplasma
Acquired ocular toxoplasmosis commonly manifests in the second through 
fourth decades [10, 30]. Approximately 10% of otherwise healthy individuals who 
contract the infection report nonspecific symptoms, such as fatigue, fever and 
myalgias. Cervical lymphadenopathy [31].
Though floaters with altered vision may be the most common symptom of 
toxoplasma retinitis, however, clinical presentation ranges a wide spectrum.
Anterior uveitis is a common finding, with mutton-fat keratic precipitates, 
fibrin, cells and flare, iris nodules and posterior synechiae [32]. Raised intraocular 
pressure has been reported in (30%–38%) of the cases [33, 34].
3.2.1 Typical toxoplasma retinitis
This usually manifests as active focal necrotizing retinitis, at the edge of an old, 
pigmented scar with overlying vitritis. Figure 2. Bosch-Driessen et al. reported 72% 
of the patients had pre-existing retinochoroidal scars, indicating prior subclinical 
disease. The pigmented scar has been described to harbor the cysts that remain 
dormant until the cyst ruptures with release of organisms into the surrounding 
retina inducing adjacent retinitis [10].
Toxoplasma retinitis may occasionally manifest without an adjacent scar. 
Figure 3. It is known that tissue cysts can exist in normal-appearing retina. The 
retina may be infected at the time of an initial systemic infection, but without clini-
cally apparent lesions at the time [32].
Figure 1. 
Colored image (left) and fundus fluorescein angiography (right) of atrophic pigmented congenital toxoplasma 
‘wagon wheel’ macular scar.
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The focus of retinitis is of necrotizing nature and usually involves the full thick-
ness of the retina, although occasional limited involvement of either inner or outer 
retina occurs, as described by Friedmann and Knox. Depending upon the thickness 
of involved retina, the overlying vitreous and underlying choroid are variably 
involved [30].
Large, full-thickness lesions tend to incite more severe vitritis, producing the 
classic ‘headlight in the fog’ sign. Optical coherence tomography (OCT) of active 
lesions can detect the level of retinal involvement, severity of choroiditis, as well 
as monitoring the regression of the lesion with treatment. Figures 4 and 5. On 
regression of the retinitis, a pigmented scar that is smaller than the actual size of the 
retinitis forms.
Punctate outer retinal toxoplasma (PORT) was first described in 1985 by Doft and 
Gass [35]. They elucidated the outer variation of punctate toxoplasmosis that primar-
ily affects the outer retinal layers of the macular area. This entity usually presents in 
younger, immunocompetent patients [35, 36]. These can be either a single or several 
deep retinal infiltrates that may extend as far as the inner plexiform layer (IPL). The 
underlying retinal pigment epithelium is interrupted with variable involvements of 
the Bruch’s membrane and choroid. These lesions have been detected in the same 
eye with typical retinal toxoplasma lesions as in Figures 6 and 7 or in eyes with no 
previous toxoplasma lesions [37]. PORT lesions resolve slowly, leaving an atrophic 
chorioretinal scar and frequently recur in adjacent areas of the macula [38].
Figure 2. 
Colored image of a supranasal peripapillary pigmented scar (yellow arrow) with adjacent area of active 
retinitis (white arrow)
Figure 3. 
Colored image of superior macular toxoplasma retinitis lesion (white arrow) without adjacent scar.
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3.2.2 Retinal vascular involvement of ocular toxoplasmosis
Inflammatory vascular involvement in acute toxoplasma retinochoroiditis 
constitutes an invariable clinical sign of the disease and was reported in (100%) of 
cases in a previous study [39].
During the acute phase of toxoplasmic retinochoroiditis, perivasculitis with 
arterial involvement in the form of multiple small periarterial plaques, previously 
Figure 4. 
OCT line scan through full thickness retinitis seen between the two white arrows with compete loss of 
architecture of inner retinal layers, with a small deep retinal infiltrate (orange arrow) and adjacent mild 
subretinal fluid. Dense localized overlying vitreous infiltration overlying the area of retinitis.
Figure 5. 
OCT line scan through active toxoplasma retinitis seen between the white arrows in the photo on the left with 
underlying choroidal involvement exhibiting a hyporeflective elevated appearance. Healed lesion in the photo 
on the right between yellow arrows shows resolved retinitis with thinned retina, decreased thickness of the 
choroid with increased choroidal transmission.
Figure 6. 
Autofluorescence showing foveal hypoautofluorescent toxoplasma lesion with an active edge, and two nasal 
PORT lesions (white arrow).
Eye Infections - Recent Advances in Diagnosis and Treatment
6
Figure 8. 
Small Kyreilles plaques along the retinal artery (white arrow) adjacent to patch of toxoplasma retinitis with 
perivenular infiltrates (yellow arrow).
described as Kyreiles plaques [40], may occur, whereas that of the vein may show 
scattered infiltration of the wall, sheathing, or both. Figure 8. Obstruction of a 
branch of the central retinal artery and vein as well as choroidal vascular occlusion 
have also been reported to occur [41–45].
The pathogenesis of vasculitis, was previously explained to be, is secondary to a 
reaction between local antigens and circulating antibody, and the beads seen along 
the vessels represent cuffs of mononuclear cells [46, 47].
Inflammation of the retinal vessels can occur in close proximity to the area of reti-
nitis. The intensity of the vascular involvement was reported to be more prominent 
were the vessel traverses the active lesion. Vasculitis may also present away from the 
actual focus of inflammation Figure 9 and involve vessels in all four quadrants [39].
Occasionally, vascular occlusion may occur when thick focal retinitis engulfs 
the course of retinal vessels, leaving a permanent area of retinal ischemia [43]. 
Figure 10. Retinal vascular occlusion has been reported to be 5% [39].
3.2.3 Optic nerve involvement in ocular toxoplasma
Optic nerve involvement may be due to parasitic invasion or reactive inflam-
mation [48–51]. Eckert et al., reported optic nerve changes in 5% of the cases. 
Figure 7. 
Left image: OCT of one of the PORT lesions in the active stage (white arrow) showing inflammatory nodular 
infiltrate breaking through the RPE and extending to the inner plexiform layer corresponding to the nasal 
PORT lesions in the autofluorescent image in Figure 6, both pointed on by white arrows. The underlying 
choroid shows thickening and loss of normal architecture. Middle image: As the lesion heals the infiltrate 
decreases in size (yellow arrow) and the choroid appears less thickened with incomplete recovery of the 
normal choroidal vasculature (green arrow). Right image: Complete recovery of the lesion with complete 
disappearance of the nodular infiltrate, leaving thinned depressed inner retinal layers (orange arrow) with 
partial recovery of the RPE and increased choroidal transmission with recovered choroidal vasculature 
(red arrow).
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In 35% of the cases, retinitis was juxtapapillary. Figure 11. In pure papillitis, the 
parasite affects the optic disc directly, causing a swollen papilla with sheathing of 
the peripapillary veins and there may be no concurrent active retinochoroiditis 
Figure 9. 
Fundus fluorescein angiography (FFA) in the left image, exhibiting superior old hypofluorescent scar with 
adjacent active retinitis (white arrow) and supranasal active satellite lesion (yellow arrow). Perivenular 
leakage in the image on the right is evident supratemporally and infratemporally (white arrow) away from the 
actual foci of active retinitis.
Figure 10. 
Supratemporal thick toxoplasma retinitis along the supratemporal vessels (white arrow in the left side 
image) with occluded vessels distal to the lesion (yellow arrow). FFA performed after healing of the retinitis 
(right image), demonstrating an atrophic patch at previous site of retinitis (orange arrow) with occluded 
supratemporal vessels and a large area of retinal ischemia (red arrows).
Figure 11. 
Multicolored images (left side photo of superior peripapillary lesion (yellow arrow). OCT line scans through 
superior peripapillary lesion exhibiting almost full thickness retinitis with overlying localized dense vitritis 
(yellow arrow) in right side photo.
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Figure 12. 
Full thickness retinitis in OCT line scan indicated by the white arrow with adjacent foveal SRF.
lesion [50]. Optic nerve involvement may induce severe visual field defects as 
well as loss of color vision [6]. Neuroretinitis has also been described as a unique 
presentation of ocular toxoplasmosis [51, 52].
3.2.4 Macular oedema in ocular toxoplasmosis
Macular oedema has been reported in 12% of toxoplasma cases [10]. Subretinal 
fluid accumulation (SRF) of variable severity, adjacent to area of retinochoroidi-
tis involving the macula, has been described. Figure 12. This was explained by. 
Khairallah, as the disrupted outer blood retinal barrier, secondary to the adjacent 
inflammatory process. Ultimately the fluid regresses as the retinitis heals [53].
Cystoid macular oedema (CME) may occur in active ocular toxoplasmosis 
with different phenotypes. Ouyang et al. reported that 7.5% of the cases pre-
sented with CME, while 2.5% presented with a huge outer retinal cyst (HORC). 
Interestingly, the same study reported that 3.5% of the cases showed cystoid 
degeneration in the inner retina next to the retinal vessels without other any 
retinal/choroidal abnormality in the macula [54].
HORC was described to be intraretinal cyst with a membranous structure 
bordering the outer border of that cyst. Figure 13. Ouyang et al., hypothesized that 
this structure represents the tissue between ELM and the inner boundary of the 
RPE (i.e., photoreceptor layer), which further suggests that the lesion represents 
an intraretinal rather than a subretinal fluid accumulation. With regression of the 
fluid, the membranous structure resumes its anatomical location in the macular 
layer architecture [55].
3.2.5 Healing of toxoplasma retinocoroditis
Toxoplasma lesions healing starts to be appreciated as the vitritis regresses and the 
toxoplasma lesion starts to show more defined borders, because cicatrization occurs 
from the periphery towards the center, with variable pigmentary hyperplasia [32].
OCT is a sensitivity tool that has been used to study toxoplasma lesions in the 
active and healed stage [55, 56]. In the acute stage, retinal necrosis is detected 
by OCT as hypereflective disorganized thickening of the neurosensory retina. 
Underlying RPE clumping and disruption of the ELM and photoreceptors is seen. 
Choroidal inflammation may occasionally occur, and is detected by OCT appearing, 
hyporeflectivite thickening and, confined underneath area of retinitis. Overlying 
toxoplasma retinitis lesions, hyperreflective vitreous aggregates settling over 
inflamed retinal surface has also been reported [55].
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As the retinitis starts to heal, the OCT scans show the hyperreflective area of 
retinitis, within the neurosensory retina starts to decrease in thickness with regress-
ing of any adjacent SRF or CME. The RPE clumping starts to be more obvious and 
may show localized heaping which is likely the commencement of the pigmentary 
scar. As the hyperreflectivity of the retinitis recedes, degenerative cystoid spaces 
occasionally develop that resolves as healing reaches a final stage. The posterior 
hyaloid starts to get thicker, may exerts vitroemacular traction, which occasionally 
may spontaneously be released, with the separation of the posterior hyaloid from 
the macular surface. Figure 14.
Occasionally, when retinitis is severe and recalcitrant to treatment, upon 
eventually evolving into the healing stage, the retinal layers exhibit severe, 
Figure 13. 
Photo on the top: Superior parafoveal full thickness retinitis demonstrated by OCT line scan with adjacent 
large cystoid area within the outer plexiform layer (yellow arrow) and a thin membranous structure by the 
white arrow in the base of the cyst-. Photo in the bottom after resolution of the inflammation the cystoid space 
regresses, and the inner retinal layer resume the normal architecture (red arrow).
Figure 14. 
OCT scan through the fovea demonstrating toxoplasma necrotizing retinitis evolving from the active stage 
into an atrophic healed scar tissue. A: Full thickness retinitis. B: The retinitis has resolved remarkably with 
evolution of small deep residual area foveally with overlying appearance of the thick posterior hyaloid. C: 
Decreased size of the residual deep hyperreflective material with adjacent degenerative cystoid spaces and 
vitreofovel tangential traction. D: As healing progresses, the posterior hyaloid detaches completely with release 
of the vitreofoveal traction. E: Complete resolution of the retinitis with atrophic appearance of the inner layers, 
resolved degenerative cyst and disrupted outer foveal layers.
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disorganization, thinning, with a fibrotic appearance, that may be laminated 
and splitted. Severe vitreomacular traction in such cases, can progress to retinal 
detachment. Figure 15.
3.2.6 Ocular complications
Reported complications of ocular toxoplasmosis include isolated retinal tear 
(6%), retinal detachment, which is usually rhegmatogenous and/or tractional (6%), 
pre-retinal membrane (7%), choroidal neovascularization (<1%), vitreous hemor-
rhage (2%), optic atrophy (4%) and cataract (5%–13%) [10, 57].
3.2.7 Atypical toxoplasma retinitis in immunocompromised
Atypical manifestations include exceptionally large, multifocal, bilateral, diffuse 
retinal involvement or panophthalmitis. Elderly, AIDS, immunocompromised indi-
vidual, or even rarely younger, immunocompetent patients as well [58] are likely to 
have specific defects in immune response that render them more at risk for atypical 
forms of toxoplasmosis [59]. This extensive toxoplasma retinitis presents similarly 
to necrotizing herpetic retinopathies, with large confluent full thickness areas of 
retinitis involving the peripheral retina and posterior pole. The thick, more densely 
yellow-white appearance of the lesion borders with a distinct, smooth contoured 
edge; and lack of hemorrhage, may distinguish these lesions from viral retinitis [60].
4. Recurrence and severity
4.1 Recurrence
Following an episode of toxoplasmic retinochoroiditis, the risk of recurrence 
is reportedly higher during the first year than during subsequent years: 29–32% of 
recurrences occur within 1 year, and 53–57% within 2 years [10, 32, 61].
Reasons for recurrences are not usually identified. They may arise from 
senescent changes in tissue cysts, with an accompanying release of parasites 
or antigens or as a result of trauma, hormonal fluctuations or even, transient 
immune responses of humoral or cellular nature [62]. Patients who are relatively 
Figure 15. 
55-year-old female patient with neglected toxoplasma retinitis a and B: Colored and OCT images respectively, 
exhibit large active retinitis involving all the macular area, with overlying dense vitritis. C and D multicolored 
and OCT images respectively, demonstrate photos after complete healing of the retinitis. D shows OCT image 
denoting complete disruption of the inner macular layers been replaced with laminated and split fibrosed tissue 
with focal area of traction parafoveally.
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young at the first presentation are at increased risk of recurrence compared to 
older patients who have been independently confirmed [63]. A larger retinal 
parasite load in younger patients is one explanation that Holland et al. offered for 
this observation [64]. In AIDS patients, recurrence is the rule in the absence of 
long-term antiparasitic therapy [65].
Pregnancy and cataract surgery have both been associated with an increased risk 
of reactivation [62, 66]. Bosch-Driessen and associates [10], reported that 9% of 
women with ocular toxoplasmosis developed recurrences during pregnancy. It has 
been hypothesized that this relationship is attributable to hormonal or immunologi-
cal changes that occur during pregnancy [67].
4.2 Severity
There is substantial variation in the severity of intraocular toxoplasma inflam-
mation, attributable to multiple host- and disease-related factors.
Individuals less than 60 years showed significantly higher incidence of having 
lesions less than1 disc area (DA) as compared to those above the age of 60, show-
ing lesions more than 1DA in size with P = 0.02. The same study reported that 
larger lesions were associated with more severe vitreous humor inflammation [57]. 
Patients with AIDS develop extensive disease and frequently reactivate, if treatment 
is discontinued [68].
5. Diagnosis
Diagnosis of ocular toxoplasmosis starts at the point where the classic retinal 
manifestation is highly suggestive of the disease. However, in many instances the 
clinical findings cannot be sufficient to confirm a diagnosis, especially in the atypi-
cal form of presentation and thus laboratory investigations are necessary.
5.1 Serum serology
Ocular disease in the context of the presence of serum IgG and IgM antibodies 
against Toxoplasma gondii measured by screening tests such as the enzyme-linked 
immunosorbent assay (ELISA) or CLIA (Chemiluminescence immune assay) is 
compatible with acute or recent infection with toxoplasma supporting the diag-
nosis [69], yet can never be confirmatory, unless a definitive test like the dye test 
(Sabin-Feldman), IFAT (indirect fluorescent antibody test), immunoblot, and 
ISAGA (immunoglobulin-M immunosorbent agglutination assay) is performed. 
Nonetheless, these methods are performed only by specialized laboratories, they are 
complex and costly [70].
If retinitis develops within a year of an acquired systemic infection, anti-toxo-
plasma IgM should be detectable, but the variable rate of decline of this Ig isotype 
also limits the usefulness of such testing. The only exception is during pregnancy, 
when maternal IgM may herald acute infection of both the mother and foetus trig-
gering urgent consultation with the obstetrician and neonatologist [71].
Since seropositivity is prevalent in most communities, the positive predictive 
value of IgG is low, and a positive IgG cannot be interpreted as indicative of active 
toxoplasmic infection. However, a rise in titer of specific IgG antibodies over a 
3-week period has been used as an indicator of recent infection [72].
In immunosuppressed subjects, positive serological tests indicate infection, 
however, negative tests do not exclude previous or concurrent infections [73].
Eye Infections - Recent Advances in Diagnosis and Treatment
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5.2 Goldman Witmer
Levels of antibodies in aqueous humor and their relationship to serum antibod-
ies may help in establishing the diagnosis of ocular toxoplasmosis [74, 75]. The 
Goldmann-Witmer coefficient (GWC) has been proposed as a valuable index of 
intraocular antibody production in active toxoplasmic retinochoroiditis in the 
immunocompetent subject [76].
(GWC) is calculated as the proportion of specific immunoglobulin (Ig)G in 
ocular fluid versus serum samples. It is determined as follows (anti-Toxoplasma IgG 
in aqueous humor/total IgG in aqueous humor)/(anti-Toxoplasma IgG in serum/
total IgG in serum). Although a ratio over one should indicate intraocular antibody 
production, this also occurs in healthy controls, and therefore a ratio of at least 
three is often preferred for certain diagnosis [77].
5.3 Polymerase chain reaction
The polymerase chain reaction (PCR) is an in-vitro method for exponentially 
replicating nucleic acids. PCR allows the detection and analysis of infinitesimal 
quantities of DNA. PCR of intraocular fluid has been extensively used to diagnosis 
infectious uveitis [78].
PCR testing of ocular sample can be useful in presumed toxoplasmosis in 
patients older than 50, in cases with inflammation (Tyndall ≥1/2+, panuveitis), 
area of retinochoroiditis>3 DA, and when ocular sampling performed within 1 week 
of presentation after onset of symptoms and up to 4 months [79, 80].
GWC testing is of better sensitivity than real time PCR, and is the preferred 
diagnostic procedure in ocular toxoplasmosis, especially if the testing is carried out 
in younger patients with quiet eyes and with smaller sized chorioretinal lesions [79].
Real time PCR confirmed the clinical diagnosis of toxoplasmosis in 62.5% of the 
cases, while the GWC confirmed in 87.5% [79]. Other studies reported that for 25 
patients who suffered from ocular toxoplasmosis, the GWC was positive in 90%, 
while PCR testing was positive in just 36% [80]. Also, Labalette et al., noted the 
aqueous PCR was positive in 60% when lesions were larger than three-disc areas, 
but in only 25% when lesions were smaller. Overall, GWC was more likely positive 
than PCR (i.e., 89% vs. 44%) in this group [81]. Also, the rates of positive PCR are 
high in aqueous humor, obtained from HIV-infected or elderly subjects presenting 
toxoplasma retinitis [82].
6. Management
No drug has been proven to cure infection [5], therefore, the aim of antibiotic 
treatment is to reduce the duration and severity of symptoms of acute intraocular 
inflammation, the risk of permanent visual impairment (by reducing the size of the 
eventual retinochoroidal scar), and the risk of recurrent episodes [83].
6.1 Indication for treatment
In immunocompetent individuals, toxoplasma retinochoroiditis typically 
resolves over a period of 1 to 2 months [84].
Previous reports indicated that toxoplasma treatment was employed if dense 
vitritis developed, retinitis is located close to the optic nerve, papillomacular area, 
or close proximity of lesions to major retinal vessels or if decreased vision occurs 
[5]. However, Holland reported the results of a survey from1991 to 2001, where 
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members of the AUS showed a shift in management over 10 years, were in favor of 
treatment of both mild and severe disease [85].
Treatment of active ocular toxoplasmosis in immunocompromised individuals 
regardless of the severity is the recommended practice with less debate [85].
6.2 Medical treatment
6.2.1 Systemic treatment
Several antimicrobial drug combinations are used to treat ocular toxoplasmosis.
6.2.1.1 Antiparasitic
Classic therapy is a combination of pyrimethamine 25 mg–50 mg daily orally with 
folinic acid 5 mg every other day and sulfadiazine 1 g four times daily orally with 
systemic corticosteroid [84].Pyrimethamine side effects include gastrointestinal and 
dermatological manifestations as well as hematological adverse events, including 
leukopenia and thrombocytopenia, that mandate monitoring of the blood picture 
regularly throughout the treatment course. 26% of the patients on this regimen were 
reported to discontinue treatment due to complications from the drugs [5].
The alternate treatment regimen is trimethoprim-sulfamethoxazole 
160 mg–800 mg twice daily orally with systemic corticosteroid, which is a well-
tolerated combination although sulfonamide-related reactions may occur. The com-
mon side effects include mild gastrointestinal symptoms and mild maculopapular 
rash. However, this regimen is relatively well tolerated with side effects requiring 
discontinuation in 4% of patients [5].
Both pyrimethamine and sulfadiazine, as well as trimethoprim-sulfamethox-
azole, have a similar mechanism of action, inhibiting tetrahydrofolate synthesis, 
thereby impacting nucleic acid synthesis of toxoplasma gondii. No reported dif-
ference in treatment results was reported when the classic or alternate treatment 
was used, however, treatment with classic therapy showed a greater reduction in 
the size of the retinal lesion than patients receiving other treatments or no treat-
ment [5]. Other reports comparing these two regiments showed different results 
and concluded that drug efficacies in terms of reduction in retinal lesion size and 
improvement in visual acuity were similar. Reduction in the size of the lesion was 
comparable between the two treatment groups been 59% for trimethoprim-sulfa-
methoxazole and 61% for classic therapy, and there was no significant difference 
in post-treatment visual acuity. Therefore, trimethoprim/sulfamethoxazole 
seems to be an acceptable alternative for the treatment of ocular toxoplasmosis 
[86, 87].
Clindamycin 300 mg orally four times daily [84], is often added to triple 
therapy, which is then referred to as ‘quadruple therapy’. Animal studies showed 
that clindamycin reduced numbers of tissue cysts [86]. However, experience 
has shown that it does not prevent recurrent disease in human beings [88]. 
Pseudomembranous colitis is a well-recognized potential complication of clindamy-
cin, as well as diarrhea. Clindamycin continues to be the most popular supplemental 
agent for treatment of patients with severe or persistent disease.
Opremcak and associates reported a series of 16 patients who were treated for 
toxoplasmic retinochoroiditis with trimethoprim (160 mg)/sulfamethoxazole 
(800 mg). Four were treated with trimethoprim/sulfamethoxazole alone, four were 
treated with trimethoprim/sulfamethoxazole and clindamycin, and eight were 
treated with trimethoprim/ sulfamethoxazole, clindamycin and oral prednisone. 
They concluded that trimethoprim/sulfamethoxazole accelerated the rate of 
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resolution of toxoplasmic retinochoroiditis and improved the visual outcomes of 
their patients, although the study was uncontrolled [89].
Atovaquone 750 mg three/four times daily orally or azithromycin 250 mg daily 
orally are two antiparasitic agents used for treatment of toxoplasma. However, 
these agents do not appear to prevent recurrent toxoplasmic retinochoroiditis 
in the human host convincing activity against encysted parasites in experiment 
systems [90, 91]. Atovaquone was well tolerated but reactivation was reported by 
Winterhalter et al., in 44% of the cases within an interval averaging 39 months. 
[92]. Azithromycin in treatment of ocular toxoplasmosis has shown regression of 
the retinitis within 1 month in 64% of the patients, however, 27% experienced 
recurrence within the first year of follow-up, thus debating the effectiveness in 
decreasing recurrences [91]. The effective potency of this drug with no reported 
side effects that needed stopping the drug while used in treatment of ocular toxo-
plasma has been reported [92].
6.2.1.2 Oral steroids
Recent research suggests that there is widespread variation for se of steroids 
in clinical practice for treating ocular toxoplasmosis. In a cross-sectional survey 
of uveitis specialists, 17% used oral corticosteroids in the treatment of ocular 
toxoplasmosis in immunocompetent patients, regardless of clinical findings. The 
other clinicians used corticosteroids for specific indications, such as severe vitreous 
inflammatory reaction (71%), decreased vision (59%), proximity of the lesions to 
the fovea or optic disc (35%), and for large lesions (5%) [93].
Oral corticosteroids are used during the active phase to reduce the retinal 
inflammation and thus further collateral tissue damage and also to prevent 
blood-retinal barrier breakdown. Furthermore, it can also reduce toxoplasma 
scarring. Steroids are usually started from 1 to 3 days after starting antipara-
sitic agent and continued for approximately 1 month. Indications for stopping 
therapy earlier include substantial improvement in the lesion appearance 
(“hardening” of lesion margins), substantial reduction of inflammatory reac-
tions, marked improvement in vision, and adverse drug effects. Occasionally, 
antiparasitic agents are continued at least 2 days after stopping corticosteroids 
[84]. Oral corticosteroids are not used in immunocompromised individuals to 
treat ocular toxoplasma, thereby reducing the risk of further suppression of 
host defenses. Clinical series have shown that the signs of ocular toxoplasmosis, 
including inflammatory signs, can respond rapidly to antiparasitic therapy alone 
in immunocompromised patients. [68, 94, 95].
6.2.2 Prophylactic treatment
Trimethoprim and sulfamethoxazole may be used in the prevention of recur-
rent attacks of ocular toxoplasmosis. Silveira et al. found that trimethoprim-
sulfamethoxazole (160 mg–800 mg), taken orally every 3 days for 20 months, 
significantly reduced the risk of recurrent toxoplasmic retinochoroiditis from 23.8% 
in untreated control subjects to 6.6% [96].
The investigators suggested a role for such preventive treatment in patients with 
a history of frequent and severe recurrences or with toxoplasmic scars adjacent to 
the fovea where any reactivation can result in profound vision loss.
The rationale behind prophylactic treatment is the fact that recurrence rates 
decrease with duration of infection, even without treatment. If the frequency of 
recurrences decreases over time, it may be useful immediately after acquired infec-
tions to suppress recurrences during the period of greatest risk [96].
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Recurrences of toxoplasmic retinochoroiditis may occur following LASIK and 
phacoemulsification with posterior chamber intraocular lens implantation [64, 97]. 
It is therefore recommended that prophylactic treatment be given to patients 2 days 
prior to surgery and to be continued for a period of 1 week.
6.2.3 Intravitreal treatment
Intravitreal clindamycin (1 mg) and dexamethasone (400 μg) have been used, 
injections can be repeated at 2-week intervals, based on a 5.6-day half-life of 
intravitreal clindamycin.
Soheilian et al. reported the results of treating patients with ocular toxoplasmo-
sis involving or threatening macula or optic nerve, or adjacent to a large vessel and/
or associated with severe vitritis with intravitreal treatment versus oral treatment 
using pyrimethamine and sulfadiazine plus prednisolone [98].
The mean number of injections in the intravitreal clindamycin was 1.6. Mean 
reduction in lesion size, increase in visual acuity and decrease in vitreous inflamma-
tion were not significantly different between groups, however, significantly reduc-
tion in size of lesions in IgM-positive patients who received classic treatment versus 
those who received intravitreal treatment was reported. This can be explained by 
the fact that a patient with acquired toxoplasmosis confronts a systemic infection 
that is treated better with systemic therapy.
The authors stressed that intravitreal clindamycin is a better alternative for 
pregnant and pediatric patients. Furthermore, the results of this study cannot be 
generalized to immunocompromised patients, monocular cases, and eyes with 
lesions inside the fovea (500 um). However, acquired toxoplasmosis confront 
systemic infection and, therefore, may benefit from systemic therapyas well, rather 
than just intravitreal injections [99].
6.2.4 Treatment of ocular toxoplasmosis during pregnancy
Bosch-Driessen and associates, reported that seven (9%) of 82 women with 
ocular toxoplasmosis developed recurrences during pregnancy [10]. Some reported, 
recurrent toxoplasma retinochoroiditis in a pregnant woman poses minimal risk to 
the fetus, and treatment is not indicated for the sole purpose of preventing vertical 
transmission [100]. However, other studies stressed that infection by toxoplasma 
will need treatment using spiramycin 1 g orally every 8 hours if a seronegative preg-
nant patient gets infected up to 18 weeks into the pregnancy or within the 6 months 
prior to pregnancy [71]. Intravitreal clindamycin can be a reasonable choice of 
treatment in pregnant mothers.
6.3 Surgical management
Vitreoretinal surgery may be indicated in cases of persistent vitreous opacities, 
tractional or rhegmatogenous retinal detachment. In the setting of severe refractory 
vitritis precluding fundus examination, pars plana vitrectomy may be used for both 
diagnostic and therapeutic purposes [85].
Retinal detachment was reported in 11.4% of the cases. 75% underwent 
pars plana vitrectomy and 25% underwent laser retinopexy. 50% presented 
with recurrent RD requiring scleral buckle. At final follow-up, all patients who 
underwent surgical repair had attached retinas; with severe vision loss of 20/200 
or worse [101].
Cataract surgery with intraocular lens implantation is often indicated in cases of 
significant lens opacification, after resolution of inflammation.
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7. Conclusion
Ocular toxoplasmosis presents in a myriad of manifestations in the eye with 
variable complications and can be vision depleting. Multimodal imaging is useful 
in carefully monitoring treatment response, detecting, regression or progression 
of toxoplasma lesions and also show complications such as vitreomacular traction, 
CNVs or even subtle SRF, that cannot be clinically detected early. Molecular biologi-
cal advances have improved the ability for diagnosis. Though current treatment 
modalities are effective in healing active disease yet does not effectively prevent 
recurrence. Further studies could be dedicated to developing antimicrobials that 
can help eradicate the disease.
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